Modified bio-Bentall operation with a rapid deployment valve.

Objective: To evaluate the early outcomes of a modified bio-Bentall operation using a rapid deployment valve (RDV) in high-risk patients, focusing on procedural efficacy, survival rates, and complications. Methods: A retrospective review of 11 consecutive patients who underwent the modified bio-Bentall operation with an RDV between January 2018 and December 2022 was conducted. Kaplan-Meier survival analysis was used to determine survival rates. Patients' baseline characteristics, operative details, and postoperative outcomes were reviewed. Results: The median patient age was 71 years. Most patients presenting with high-risk conditions and significant comorbidities, including inflammatory conditions, chronic lung diseases, and advanced cardiac dysfunction. The median EuroSCORE II was 10.03%. The median aortic cross-clamping and cardiopulmonary bypass times were 73.0 minutes and 99.0 minutes, respectively. No early mortalities or reoperations occurred. Two patients (14.3%) required extracorporeal membrane oxygenation support because of low cardiac output and arrhythmias, and 3 patients (23.1%) required permanent pacemaker insertion. No paravalvular leakage or valve detachment was observed during follow-up. The 1-year survival rate was 90.9%, and the 3-year survival rate was 54.5%. Six patients died during a median follow-up of 35 months, from causes including respiratory complications, gastric cancer, and undetermined factors. Conclusions: Our initial experience with the modified bio-Bentall operation using an RDV shows favorable early outcomes in relatively high-risk patients. Further validation with larger datasets and long-term follow-up is needed to validate these results.